A phase 3 trial (LITESPARK-022) reported that adding belzutifan, a HIF‑2α inhibitor, to pembrolizumab significantly improved disease‑free survival in patients with clear‑cell renal cell carcinoma at high risk for recurrence after surgery. Novartis presented the findings; investigators emphasized the adjuvant setting data as the primary outcome. The lead sentence: the combo reduced recurrence events versus control in the trial population. The study names and endpoints were disclosed by Novartis at the trial readout. Belzutifan targets hypoxia‑inducible factor‑2α, a driver in ccRCC biology, while pembrolizumab is an established PD‑1 checkpoint inhibitor. The result provides a potential new adjuvant regimen and will shape regulatory and commercial strategies if overall survival and longer follow‑up corroborate disease‑free survival gains. Further details on subgroup responses, safety signals, and planned regulatory filings were discussed by the sponsor; clinicians will watch maturation and comparative effectiveness versus other adjuvant approaches. For context: HIF‑2α inhibitors are a newer targeted class, and pairing them with immunotherapy marks a meaningful strategic shift in post‑surgical kidney cancer management.